Narcolepsy after the orexin approval: #$ALKS, #$AXSM, #$JAZZ and #$TAK
www.merlintrader.com/narcolepsy-o...
www.merlintrader.com/narcolepsy-o...
September 25, 2026 at 6:40 PM
Narcolepsy after the orexin approval: #$ALKS, #$AXSM, #$JAZZ and #$TAK
www.merlintrader.com/narcolepsy-o...
www.merlintrader.com/narcolepsy-o...
Axsome Therapeutics $AXSM: Truist Securities raised its price target from $200.00 to $285.00 and maintained its Buy rating.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
September 23, 2026 at 4:15 PM
Axsome Therapeutics $AXSM: Truist Securities raised its price target from $200.00 to $285.00 and maintained its Buy rating.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
Petite curiosité, voici quelques photos envoyées par Paul, un abonné de la chaine, qui montrent les entrailles de son lecteur de carte mémoire AXSM pour caméra numérique 4K de cinéma Sony (type CineAlta PMW-F55). Prix du lecteur seul : $3870, prix de la caméra équipée : environ $60.000
September 17, 2023 at 8:57 AM
Petite curiosité, voici quelques photos envoyées par Paul, un abonné de la chaine, qui montrent les entrailles de son lecteur de carte mémoire AXSM pour caméra numérique 4K de cinéma Sony (type CineAlta PMW-F55). Prix du lecteur seul : $3870, prix de la caméra équipée : environ $60.000
AXSM +865% in 308 days. Back in March 2019 a base breakout was there to catch early at a 9.04 close, and the trend did the rest into a 109.94 peak while the company had no earnings. Full analysis of the trade: https://trendsandbreakouts.com/axsm-base-breakout-2019 #trading #breakout
AXSM +865%: base breakout on a clinical-stage biotech, March 2019
AXSM +865% in 308 days. Back in March 2019 a base breakout was there to catch early at a 9.04 close, and the trend did the rest into a 109.94 peak while the company had no earnings. Full analysis of the trade: https://trendsandbreakouts.com/axsm-base-breakout-2019 #trading #breakout
trendsandbreakouts.com
July 17, 2026 at 7:36 PM
AXSM +865% in 308 days. Back in March 2019 a base breakout was there to catch early at a 9.04 close, and the trend did the rest into a 109.94 peak while the company had no earnings. Full analysis of the trade: https://trendsandbreakouts.com/axsm-base-breakout-2019 #trading #breakout
JUST IN: ( NASDAQ: #AXSM ) Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
#StockMarket #News
#StockMarket #News
November 12, 2024 at 8:50 PM
JUST IN: ( NASDAQ: #AXSM ) Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
#StockMarket #News
#StockMarket #News
NEWS: ( NASDAQ: #AXSM ) Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
#StockMarket #News
#StockMarket #News
September 4, 2024 at 5:25 PM
My latest @forbes.com feature profiles Herriot Tabuteau, a Haitian immigrant, Yale-educated doctor + longtime investor, who started Axsome to tackle brain disorders. Now $AXSM has 3 drugs on the mkt + 5 more in the pipeline: “We’re not a small co in terms of ambition.”
www.forbes.com/sites/amyfel...
www.forbes.com/sites/amyfel...
This Haiti-Born Doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’s
Herriot Tabuteau combined his Yale medical degree and two decades in finance to start Axsome Therapeutics. Now the company has three drugs on the market and five more in the pipeline.
www.forbes.com
October 1, 2025 at 1:59 PM
My latest @forbes.com feature profiles Herriot Tabuteau, a Haitian immigrant, Yale-educated doctor + longtime investor, who started Axsome to tackle brain disorders. Now $AXSM has 3 drugs on the mkt + 5 more in the pipeline: “We’re not a small co in terms of ambition.”
www.forbes.com/sites/amyfel...
www.forbes.com/sites/amyfel...
Axsome Q2 Revenue Rises 46% But Misses Estimates as Soaring Costs Widen Net Loss https://signalbloom.ai/news/AXSM/axsome-q2-revenue-rises-46-but-misses-estimates-as-soaring-costs-widen-net-loss $AXSM #Earnings via @signalbloom.ai
August 10, 2026 at 11:10 AM
Axsome Q2 Revenue Rises 46% But Misses Estimates as Soaring Costs Widen Net Loss https://signalbloom.ai/news/AXSM/axsome-q2-revenue-rises-46-but-misses-estimates-as-soaring-costs-widen-net-loss $AXSM #Earnings via @signalbloom.ai
🏥 #AXSM +18% | FDA accepts AXS-05 for Alzheimer's agitation with Priority Review | PDUFA target April 30, 2026 | Strong catalyst next year | Watch multiple pipeline catalysts
December 31, 2025 at 7:00 PM
🏥 #AXSM +18% | FDA accepts AXS-05 for Alzheimer's agitation with Priority Review | PDUFA target April 30, 2026 | Strong catalyst next year | Watch multiple pipeline catalysts
BioPharmCatalyst Weekly #Watchlist
Key Phase 3 Catalysts Left for the Quarter
$PTGX $IMVT $ALKS $PRAX $CELC $ARVN $GYRE $BCRX $MURA $AXSM $KPTI
www.biopharmcatalyst.com/news/2025/ke...
Key Phase 3 Catalysts Left for the Quarter
$PTGX $IMVT $ALKS $PRAX $CELC $ARVN $GYRE $BCRX $MURA $AXSM $KPTI
www.biopharmcatalyst.com/news/2025/ke...
February 14, 2025 at 9:46 PM
BioPharmCatalyst Weekly #Watchlist
Key Phase 3 Catalysts Left for the Quarter
$PTGX $IMVT $ALKS $PRAX $CELC $ARVN $GYRE $BCRX $MURA $AXSM $KPTI
www.biopharmcatalyst.com/news/2025/ke...
Key Phase 3 Catalysts Left for the Quarter
$PTGX $IMVT $ALKS $PRAX $CELC $ARVN $GYRE $BCRX $MURA $AXSM $KPTI
www.biopharmcatalyst.com/news/2025/ke...
BioPharmCatalyst Weekly #Watchlist
Key catalysts left for the quarter; Countdown to the end of the quarter
$ARVN $AXSM $BDTX $CELC $CRVO $DRMA $GYRE $MIST $NRBO $PTGX $RHHBY $RNA $RNA $TRVI $UBX $VSTM $WVE
www.biopharmcatalyst.com/news/2025/ke...
Key catalysts left for the quarter; Countdown to the end of the quarter
$ARVN $AXSM $BDTX $CELC $CRVO $DRMA $GYRE $MIST $NRBO $PTGX $RHHBY $RNA $RNA $TRVI $UBX $VSTM $WVE
www.biopharmcatalyst.com/news/2025/ke...
March 7, 2025 at 9:51 PM
BioPharmCatalyst Weekly #Watchlist
Key catalysts left for the quarter; Countdown to the end of the quarter
$ARVN $AXSM $BDTX $CELC $CRVO $DRMA $GYRE $MIST $NRBO $PTGX $RHHBY $RNA $RNA $TRVI $UBX $VSTM $WVE
www.biopharmcatalyst.com/news/2025/ke...
Key catalysts left for the quarter; Countdown to the end of the quarter
$ARVN $AXSM $BDTX $CELC $CRVO $DRMA $GYRE $MIST $NRBO $PTGX $RHHBY $RNA $RNA $TRVI $UBX $VSTM $WVE
www.biopharmcatalyst.com/news/2025/ke...
#BiotechHangout: Chris Garabedian, Graig Suvannavejh, Paul Matteis, Tess Cameron on markets: tech/biotech decoupling, VC investment, PIPEs/RM opportunities, deals & raises: $JAZZ/Actio, #$ABCL, #$SLN, data: #$DFTX, #$CGEM, #$NBIX, #$AMGN, company news: #$BLTE, #$AXSM policy: BINSA, China bit.ly/4xJBSFh
August 14, 2026 at 1:10 PM
#BiotechHangout: Chris Garabedian, Graig Suvannavejh, Paul Matteis, Tess Cameron on markets: tech/biotech decoupling, VC investment, PIPEs/RM opportunities, deals & raises: $JAZZ/Actio, #$ABCL, #$SLN, data: #$DFTX, #$CGEM, #$NBIX, #$AMGN, company news: #$BLTE, #$AXSM policy: BINSA, China bit.ly/4xJBSFh
If you're watching biotech, this one's worth a look. Auvelity just made history with an FDA approval that could reshape Alzheimer's agitation treatment. Read more: aktiego.com/market-analy... #Healthcare #Investing #$AXSM
Auvelity FDA Approval Launches the First Non-Antipsychotic Market for Alzheimer Agitation - AktieGo
Gilead’s BIC/LEN HIV combination has an August 27 PDUFA. Auvelity is the first non-antipsychotic approved for Alzheimer’s agitation. GEn1E got dual FDA designations for DMD. The US-Iran peace deal rem...
aktiego.com
July 6, 2026 at 8:21 PM
If you're watching biotech, this one's worth a look. Auvelity just made history with an FDA approval that could reshape Alzheimer's agitation treatment. Read more: aktiego.com/market-analy... #Healthcare #Investing #$AXSM
Axsome Therapeutics ($AXSM) Stock Hub 2026: SUMMIT Phase 3 Starts as AUVELITY’s Alzheimer’s Launch Enters Its First Full Quarter
https://merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/
https://merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/
$AXSM Stock Hub 2026: Axsome Q2 Revenue, Pipeline, Catalysts
Axsome Therapeutics ($AXSM) Q2 2026: revenue $218.4M, net loss $51.3M, cash $319.9M. AUVELITY Alzheimer's agitation launch, AXS-12 PDUFA May 1 2027, pipeline, debt and insider activity. Not investment advice.
merlintrader.com
September 18, 2026 at 10:48 AM
Axsome Therapeutics ($AXSM) Stock Hub 2026: SUMMIT Phase 3 Starts as AUVELITY’s Alzheimer’s Launch Enters Its First Full Quarter
https://merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/
https://merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/
#BiotechHangout: Daphne Zohar, Paul Matteis, Brian Skorney, Tim Opler, Abe Ceesay on $XBI, market sentiment, positive investor mood, PIPES re-emerging, M&A, neuro: $GHRS data, psychedelics, $AXSM approval, anti-VEGF therapy comp dynamics, $ALMS/$SLRN, $HIMS commercial,Trump tariffs: bit.ly/3CFAoVz
February 7, 2025 at 2:05 PM
#BiotechHangout: Daphne Zohar, Paul Matteis, Brian Skorney, Tim Opler, Abe Ceesay on $XBI, market sentiment, positive investor mood, PIPES re-emerging, M&A, neuro: $GHRS data, psychedelics, $AXSM approval, anti-VEGF therapy comp dynamics, $ALMS/$SLRN, $HIMS commercial,Trump tariffs: bit.ly/3CFAoVz
Axsome Therapeutics ($AXSM) reported EPS of -0.8(Adj) beating estimate of -0.99 for Q4 2024. Revenue 118.766 Million Vs 117.83 Million expected.
https://fundspec.io
Build Sophisticated AI driven valuation and momentum models on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Build Sophisticated AI driven valuation and momentum models on the FundSpec App available on the AppStore or PlayStore!
February 18, 2025 at 12:38 PM
Axsome Therapeutics ($AXSM) reported EPS of -0.8(Adj) beating estimate of -0.99 for Q4 2024. Revenue 118.766 Million Vs 117.83 Million expected.
https://fundspec.io
Build Sophisticated AI driven valuation and momentum models on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Build Sophisticated AI driven valuation and momentum models on the FundSpec App available on the AppStore or PlayStore!
$PLRX paused enrollment and dosing in its Phase 2b BEACON-IPF trial of bexotegrast for idiopathic pulmonary fibrosis following a review by the independent Data Safety Monitoring Board.
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pl...
$PLRX $BDRX $OCEA $NLSP $AXSM $SERA
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pl...
$PLRX $BDRX $OCEA $NLSP $AXSM $SERA
February 10, 2025 at 9:29 PM
$PLRX paused enrollment and dosing in its Phase 2b BEACON-IPF trial of bexotegrast for idiopathic pulmonary fibrosis following a review by the independent Data Safety Monitoring Board.
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pl...
$PLRX $BDRX $OCEA $NLSP $AXSM $SERA
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pl...
$PLRX $BDRX $OCEA $NLSP $AXSM $SERA
#trading #premarket #stocks
See StockQuakes.com
Stock Premarket - Dec 30, 2024
UP
↑ WATT Energous
↑ NLSP Nls Pharma
↑ INTZ Intrusion
↑ OCTO Eightco
↑ CTM Castellum
DOWN
↓ LIDR Aeye
↓ TRAW Traws Pharma
↓ LAES Sealsq Corp
↓ AXSM Axsome Therapeutics
↓ RGTI Rigetti
See StockQuakes.com
Stock Premarket - Dec 30, 2024
UP
↑ WATT Energous
↑ NLSP Nls Pharma
↑ INTZ Intrusion
↑ OCTO Eightco
↑ CTM Castellum
DOWN
↓ LIDR Aeye
↓ TRAW Traws Pharma
↓ LAES Sealsq Corp
↓ AXSM Axsome Therapeutics
↓ RGTI Rigetti
StockQuakes - AI Stock Analysis
Using AI to find stock market opportunities.
StockQuakes.com
December 30, 2024 at 1:43 PM
#trading #premarket #stocks
See StockQuakes.com
Stock Premarket - Dec 30, 2024
UP
↑ WATT Energous
↑ NLSP Nls Pharma
↑ INTZ Intrusion
↑ OCTO Eightco
↑ CTM Castellum
DOWN
↓ LIDR Aeye
↓ TRAW Traws Pharma
↓ LAES Sealsq Corp
↓ AXSM Axsome Therapeutics
↓ RGTI Rigetti
See StockQuakes.com
Stock Premarket - Dec 30, 2024
UP
↑ WATT Energous
↑ NLSP Nls Pharma
↑ INTZ Intrusion
↑ OCTO Eightco
↑ CTM Castellum
DOWN
↓ LIDR Aeye
↓ TRAW Traws Pharma
↓ LAES Sealsq Corp
↓ AXSM Axsome Therapeutics
↓ RGTI Rigetti
SHOP $SOUN $MARA $BABA $CAVA $SPOT $AMAT $DIS $PLUG $HD $MNDY $OXY $RKLB $BSEM $ZETA $SE $RKT $CSCO $ASTS $WULF $ONON $OKLO $HUT $NVAX $HTZ $LUNR $CART $TLN $BITF $GRAB $JD $LAZR $ALT $CRON $ICL $NICE $CYBR $BXSL $DESP $ARMK $TSN $RUM $PGY $TGI $AAP $AXSM $AZN $BILI $LINC $LQDA
November 15, 2024 at 12:59 AM
SHOP $SOUN $MARA $BABA $CAVA $SPOT $AMAT $DIS $PLUG $HD $MNDY $OXY $RKLB $BSEM $ZETA $SE $RKT $CSCO $ASTS $WULF $ONON $OKLO $HUT $NVAX $HTZ $LUNR $CART $TLN $BITF $GRAB $JD $LAZR $ALT $CRON $ICL $NICE $CYBR $BXSL $DESP $ARMK $TSN $RUM $PGY $TGI $AAP $AXSM $AZN $BILI $LINC $LQDA
#earnings for the week of February 19, 2024
$NVDA $PANW $SQ $WMT $RIVN $ETSY $HD $CVNA $MELI $VRT $SNPS $MRNA $LCID $SEDG $MPW $O $TDOC $NOVA $NEM $NKLA $WBD $NU $ARDX $BKNG $BROS $ENVX $AXSM $LNG $FVRR $MDT $ADI $CZR $W $APA $FANG $NEO $MRO $SU $MOS…
$NVDA $PANW $SQ $WMT $RIVN $ETSY $HD $CVNA $MELI $VRT $SNPS $MRNA $LCID $SEDG $MPW $O $TDOC $NOVA $NEM $NKLA $WBD $NU $ARDX $BKNG $BROS $ENVX $AXSM $LNG $FVRR $MDT $ADI $CZR $W $APA $FANG $NEO $MRO $SU $MOS…
February 16, 2024 at 2:39 PM
#earnings for the week of February 19, 2024
$NVDA $PANW $SQ $WMT $RIVN $ETSY $HD $CVNA $MELI $VRT $SNPS $MRNA $LCID $SEDG $MPW $O $TDOC $NOVA $NEM $NKLA $WBD $NU $ARDX $BKNG $BROS $ENVX $AXSM $LNG $FVRR $MDT $ADI $CZR $W $APA $FANG $NEO $MRO $SU $MOS…
$NVDA $PANW $SQ $WMT $RIVN $ETSY $HD $CVNA $MELI $VRT $SNPS $MRNA $LCID $SEDG $MPW $O $TDOC $NOVA $NEM $NKLA $WBD $NU $ARDX $BKNG $BROS $ENVX $AXSM $LNG $FVRR $MDT $ADI $CZR $W $APA $FANG $NEO $MRO $SU $MOS…
📊 #Earnings Winners & Losers – Feb 18, 2025! 🚀📉
🏆 Winners:
✅ #Baidu ($BIDU) – EPS $2.64 vs. $1.78 est. 💰
✅ Occidental Petroleum ($OXY) – Revenue $7.13B 📈
💥 Losers:
❌ Community Health ($CYH) – EPS - $0.42 vs. $0.05 est. 😬
❌ Axsome Therapeutics ($AXSM) – EPS - $3.96 vs. - $0.90 est. 📉
#stocks
🏆 Winners:
✅ #Baidu ($BIDU) – EPS $2.64 vs. $1.78 est. 💰
✅ Occidental Petroleum ($OXY) – Revenue $7.13B 📈
💥 Losers:
❌ Community Health ($CYH) – EPS - $0.42 vs. $0.05 est. 😬
❌ Axsome Therapeutics ($AXSM) – EPS - $3.96 vs. - $0.90 est. 📉
#stocks
February 18, 2025 at 11:51 PM
Imo, Axsome Therapeutics (Ticker: AXSM) has considerable downside at this valuation of $3B+ mkt cap. It's shocking the FDA approved their drug that combines DM cough syrup and Wellbutrin without making the company run tox studies, a DM cough syrup monotherapy arm, abuse potential studies, nothing.
October 12, 2023 at 3:53 PM
Imo, Axsome Therapeutics (Ticker: AXSM) has considerable downside at this valuation of $3B+ mkt cap. It's shocking the FDA approved their drug that combines DM cough syrup and Wellbutrin without making the company run tox studies, a DM cough syrup monotherapy arm, abuse potential studies, nothing.